A narrative review on diagnosis and treatment of ifosfamide-induced encephalopathy, the perspective of a EURACAN reference center for sarcomas. (2025)

Peer-Reviewed Study · Torchia A; Vari S; Onesti CE; Ceddia S; Maschio M; Maggi G; Riva F; Faltyn W; Russillo M; Ferraresi V · February 21, 2025

Torchia A et al., 2025-02-21: Narrative review from a European sarcoma reference centre recording methylene blue as the most used pharmacological treatment for ifosfamide-induced encephalopathy, with efficacy as curative and prophylactic treatment studied but results mixed.

The most used pharmacological treatment is methylene blue, whose efficacy both as a curative and a prophylactic treatment has been the object of many studies, with mixed results.

Torchia A et al., 2025-02-21: Narrative review from a European sarcoma reference centre recording methylene blue as the most used pharmacological treatment for ifosfamide-induced encephalopathy, with efficacy as curative and prophylactic treatment studied but results mixed. C7 Torchia 2025 (the real chemotherapy-adjunct use the source does not mention). Study type: narrative review (EURACAN reference centre for sarcomas, Italy). Country: Italy. Dose/route: the abstract does not give a dose or route for methylene blue in IIE. Funder: not stated in the record. Conflicts: 'The authors declare that the research was conducted in the absence of any commercial or financial relationships…'. Note this is a DIFFERENT mechanism from chemosensitisation: methylene blue is used to treat a chemotherapy toxicity, not to make tumours more sensitive. Also filed as MTI-68, MTM-23, MTO-66 (claims C10, C4, C6, C7). Study type: review.